Prestige BioPharma Limited Korean Deposit Receipt Repr 1/5 Sh (950210) Financial Statements

― Followers

Prestige BioPharma Limited Korean Deposit Receipt Repr 1/5 Sh Financial Overview

Prestige BioPharma Limited Korean Deposit Receipt Repr 1/5 Sh's market cap is currently ₩432.69B. The company's EPS TTM is ₩-957.25; its P/E ratio is -7.32; Prestige BioPharma Limited Korean Deposit Receipt Repr 1/5 Sh is scheduled to report earnings on ―, and the estimated EPS forecast is ₩―. See an overview of income statement, balance sheet, and cash flow financials.

	Jun 25	Jun 23	Jun 22	Jun 22	Jun 21
Income Statement
Total Revenue	₩ 14.31B	₩ 689.08M	₩ 0.00	₩ 161.84M	₩ 0.00
Gross Profit	₩ -24.01B	₩ -528.79M	₩ -3.87B	₩ 127.90M	₩ -1.67B
Operating Income	₩ -67.28B	₩ -62.78B	₩ -118.82B	₩ 1.03B	₩ -18.38B
EBITDA	₩ 33.31B	₩ -31.05B	₩ -206.91B	₩ 10.51B	₩ -5.68B
Net Income	₩ 22.27B	₩ -32.92B	₩ -211.45B	₩ 17.57B	₩ -7.39B
Balance Sheet
Cash & Short-Term Investments	₩ 173.71B	₩ 228.81B	₩ 303.27B	₩ 301.41B	₩ 459.35B
Total Assets	₩ 741.92B	₩ 711.72B	₩ 499.81B	₩ 741.60B	₩ 604.17B
Total Debt	₩ 144.18B	₩ 89.67B	₩ 4.25B	₩ 86.18B	₩ 7.77B
Net Debt	₩ 28.66B	₩ -129.77B	₩ -264.40B	₩ -38.85B	₩ -451.20B
Total Liabilities	₩ 236.15B	₩ 196.22B	₩ 69.88B	₩ 195.37B	₩ 29.21B
Stockholders' Equity	₩ 408.95B	₩ 439.09B	₩ 429.94B	₩ 450.51B	₩ 574.96B
Cash Flow
Free Cash Flow	₩ -95.04B	₩ -76.02B	₩ -114.02B	₩ -125.89B	₩ -33.56B
Operating Cash Flow	₩ -54.34B	₩ -48.03B	₩ -45.91B	₩ -60.27B	₩ -15.45B
Investing Cash Flow	₩ -99.43B	₩ 132.46B	₩ -184.69B	₩ -148.61B	₩ -20.91B
Financing Cash Flow	₩ 49.81B	₩ -1.46B	₩ -4.50B	₩ 53.18B	₩ 454.52B

Currency in KRW

Prestige BioPharma Limited Korean Deposit Receipt Repr 1/5 Sh Earnings and Revenue History

Income Statement >

Prestige BioPharma Limited Korean Deposit Receipt Repr 1/5 Sh Debt to Assets

Balance Sheet >

Prestige BioPharma Limited Korean Deposit Receipt Repr 1/5 Sh Cash Flow

Cash Flow >

Prestige BioPharma Limited Korean Deposit Receipt Repr 1/5 Sh Forecast EPS vs Actual EPS

Earnings >